Combined Polyamine Key Nanoformulations as Anticancer Therapeutics: Review of the Evidence
International Journal of Nanomedicine · 2026-11 · Volume 21 · 1-16
DOI: 10.2147/ijn.s656362 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Nanomedicine, 2026-11. Verfasst von Qiang Li und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of General Surgery, Shidong Hospital Affiliated to University of Shanghai for Science and Technology, Shanghai, People's Republic of China. Hauptthemen laut MEDLINE: Polyamines, Antineoplastic Agents, Neoplasms, Nanoparticle Drug Delivery System. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).
Abstract (Originalsprache)
Polyamine metabolism offers several entry points for cancer nanotherapy, but pathway inhibition, carrier uptake and catalytic cytotoxicity require different evidence. This review examines how nanosystems address compensatory polyamine uptake, normal-tissue exposure and mismatched delivery of combination treatments. We organize the literature by four non-exclusive mechanisms: Deplete reduces a required polyamine pool; Disrupt alters feedback or releases active analogs; Exploit uses experimentally demonstrated transport-associated uptake; and Convert transforms polyamines into reactive products. Representative systems include self-immolative analog carriers, polyamine-decorated particles and enzyme-containing frameworks or local hydrogels. Their reported advantages remain dependent on formulation, administration route and tumor model. We connect material properties to target engagement, adaptive glutamine and arginine metabolism, immune effects and the controls needed to establish a causal nano-enabled benefit. Clinical efficacy of conventional eflornithine in a defined neuroblastoma setting provides pathway validation, whereas the polyamine-directed nanosystems reviewed here remain preclinical. Translation requires exposure-matched comparisons, quantitative tumor-to-normal-tissue pharmacology, repeat-dose recovery and reproducible manufacturing. The framework is intended to guide experimental design and critical comparison, rather than to imply that all platforms share efficacy, selectivity or clinical readiness.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of General Surgery, Shidong Hospital Affiliated to University of Shanghai for Science and Technology, Shanghai, People's Republic of China.
- School of Health Science and Engineering, University of Shanghai for Science and Technology, Shanghai, People's Republic of China.
- School of Biomedical Engineering, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, People's Republic of China.
- Jiangsu Provincial Key Laboratory of Multimodal Digital Twin Technology, Suzhou Institute for Advanced Research, University of Science and Technology of China, Suzhou, People's Republic of China.
ORCID-Profile: Jingwen Tang, Shengtao Wang
Zitieren
APA
Li, Q., Lin, H., Liu, M., Tang, J., Zhang, R., Hou, H., Wang, S., & Wang, Y. (2026). Combined Polyamine Key Nanoformulations as Anticancer Therapeutics: Review of the Evidence. International Journal of Nanomedicine, Volume 21, 1-16. https://doi.org/10.2147/ijn.s656362
Vancouver
Li Q, Lin H, Liu M, Tang J, Zhang R, Hou H, et al. Combined Polyamine Key Nanoformulations as Anticancer Therapeutics: Review of the Evidence. International Journal of Nanomedicine. 2026;Volume 21:1-16. doi:10.2147/ijn.s656362
BibTeX
@article{Li2026,
author = {Li, Qiang and Lin, Hui and Liu, Mengnan and Tang, Jingwen and Zhang, Ruizhi and Hou, Huihui and Wang, Shengtao and Wang, Yuehua},
title = {Combined Polyamine Key Nanoformulations as Anticancer Therapeutics: Review of the Evidence},
journal = {International Journal of Nanomedicine},
year = {2026},
volume = {Volume 21},
pages = {1--16},
doi = {10.2147/ijn.s656362}
}
EUVIMED